<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2850">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04527471</url>
  </required_header>
  <id_info>
    <org_study_id>RPL554-COV-201</org_study_id>
    <nct_id>NCT04527471</nct_id>
  </id_info>
  <brief_title>Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19</brief_title>
  <official_title>A Single-center, Pilot, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ensifentrine in the Recovery of Hospitalized Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Verona Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Verona Pharma plc</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study is being performed to assess the efficacy and safety of inhaled ensifentrine&#xD;
      delivered via pMDI compared with a matching placebo in conjunction with standard of care&#xD;
      treatments on recovery in patients hospitalized due to COVID-19 infection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 4, 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with recovery</measure>
    <time_frame>Day 29</time_frame>
    <description>Recovery = first day on which subject satisfies one of the following categories: not hospitalized, no limitations of activities; or not hospitalized, limitation of activities, home oxygen requirement, or both.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to recovery</measure>
    <time_frame>Day 1 to Day 29</time_frame>
    <description>Recovery = first day on which subject satisfies one of the following categories: not hospitalized, no limitations of activities; or not hospitalized, limitation of activities, home oxygen requirement, or both.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with recovery</measure>
    <time_frame>Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with improvement (from Day 1) of one category using the 7-point ordinal scale</measure>
    <time_frame>Days 7, 14 and 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with improvement (from Day 1) of two categories using the 7-point ordinal scale</measure>
    <time_frame>Days 7, 14 and 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>Days 29 and 60</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients alive and not in respiratory failure</measure>
    <time_frame>Day 29</time_frame>
    <description>respiratory failure = requiring invasive mechanical ventilation or extracorporeal membrane oxygenation [ECMO]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients needing re-hospitalization</measure>
    <time_frame>Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization from Day 1</measure>
    <time_frame>Day 1 to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in 7-point ordinal scale</measure>
    <time_frame>Days 7, 14 and 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total time on supplemental oxygen</measure>
    <time_frame>Day 1 to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of new non-invasive ventilation or high flow oxygen use</measure>
    <time_frame>Day 1 to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of new non-invasive ventilation or high flow oxygen use</measure>
    <time_frame>Day 1 to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of new oxygen use</measure>
    <time_frame>Day 1 to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of new oxygen use</measure>
    <time_frame>Day 1 to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of new mechanical ventilator use</measure>
    <time_frame>Day 1 to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of new mechanical ventilator use</measure>
    <time_frame>Day 1 to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients receiving invasive mechanical ventilation or ECMO</measure>
    <time_frame>Days 7, 14 and 29</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>Day 60</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Respiration Rate</measure>
    <time_frame>Day 1 to Day 29</time_frame>
    <description>breaths/minute</description>
  </other_outcome>
  <other_outcome>
    <measure>Heart Rate</measure>
    <time_frame>Day 1 to Day 29</time_frame>
    <description>beats/minute</description>
  </other_outcome>
  <other_outcome>
    <measure>Body Temperature</measure>
    <time_frame>Day 1 to Day 29</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>Day 1 to Day 29</time_frame>
    <description>mmHg</description>
  </other_outcome>
  <other_outcome>
    <measure>Level of Consciousness</measure>
    <time_frame>Day 1 to Day 29</time_frame>
    <description>AVPU scale</description>
  </other_outcome>
  <other_outcome>
    <measure>Oxygen saturation</measure>
    <time_frame>Day 1 to Day 29</time_frame>
    <description>SpO2 %</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Coronavirus Infection</condition>
  <condition>Covid-19</condition>
  <condition>SARS-CoV-2</condition>
  <arm_group>
    <arm_group_label>Ensifentrine + Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 subjects randomized to receive blinded, inhaled ensifentrine in addition to standard of care treatment for COVID-19 infection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Standard of Care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>15 subjects randomized to receive blinded, inhaled placebo in addition to standard of care treatment for COVID-19 infection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ensifentrine Dose 1</intervention_name>
    <description>Study drug delivered twice daily via pMDI</description>
    <arm_group_label>Ensifentrine + Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo pMDI</intervention_name>
    <description>Placebo delivered twice daily via pMDI</description>
    <arm_group_label>Placebo + Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Capable of giving informed consent indicating that they understand the purpose of the&#xD;
             study and study procedures and agree to comply with the requirements and restrictions&#xD;
             listed in the informed consent form and in this protocol.&#xD;
&#xD;
          -  Patient must be at least 18 years of age and less than or equal to 80 years of age at&#xD;
             the time of informed consent.&#xD;
&#xD;
          -  Males are eligible to participate or females of non-childbearing potential or WOCBP&#xD;
             who have a negative pregnancy test at screening are eligible to participate. WOCBP and&#xD;
             female partners of male participants agree to either abstinence or use at least one&#xD;
             primary form of highly effective contraception not including hormonal contraception&#xD;
             from the time of screening through Day 60 following the first dose of study&#xD;
             medication.&#xD;
&#xD;
          -  Clinical status consistent with 3, 4 or 5 on the Ordinal scale: Hospitalized, not&#xD;
             requiring supplemental oxygen; Hospitalized, requiring any supplemental oxygen;&#xD;
             Hospitalized, requiring non-invasive ventilation or use of high flow oxygen devices.&#xD;
&#xD;
          -  Admission to hospital AND have a confirmed diagnosis of severe acute respiratory&#xD;
             syndrome coronavirus (SARS-COV-2) infection confirmed by polymerase chain reaction&#xD;
             (PCR) test AND displays at least one of the following: Respiratory rate &gt; 24 breaths&#xD;
             per minute; new cough; new atypical chest pain; new dyspnea; oxygen saturation &lt; 97%&#xD;
             at rest; chest x-ray with new changes consistent with COVID-related airspace disease.&#xD;
&#xD;
          -  Capable of complying with all study restrictions and procedures including ability to&#xD;
             use the pMDI correctly.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in any other clinical trial of an experimental treatment for COVID-19,&#xD;
             unless related to an expanded access program as part of Standard of Care at screening&#xD;
             or during study.&#xD;
&#xD;
          -  Evidence of multiorgan failure.&#xD;
&#xD;
          -  Requiring mechanical ventilation at screening.&#xD;
&#xD;
          -  Alanine Aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 5 X upper limit&#xD;
             of normal (ULN) at screening.&#xD;
&#xD;
          -  Creatinine clearance &lt; 30 mL/min at screening.&#xD;
&#xD;
          -  Pregnancy or lactation at screening.&#xD;
&#xD;
          -  Allergy or other contraindication or one of ensifentrine.&#xD;
&#xD;
          -  In the opinion of the clinical team, progression to death is imminent and inevitable&#xD;
             within the next 24 hours, irrespective of the provision of treatments.&#xD;
&#xD;
          -  Use of prohibited medications (theophylline, PDE4 inhibitors [e.g. roflumilast,&#xD;
             apremilast, crisaborole] within 48 hours of screening or during study)&#xD;
&#xD;
          -  Any other reason that the Investigator considers makes the patient unsuitable to&#xD;
             participate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 6, 2020</study_first_submitted>
  <study_first_submitted_qc>August 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2020</study_first_posted>
  <last_update_submitted>January 14, 2021</last_update_submitted>
  <last_update_submitted_qc>January 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Verona Pharma will not be sharing individual deidentified participant data or other relevant study documents.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

